Modern Wealth Management LLC Makes New Investment in Relx Plc $RELX

Key Points

• Modern Wealth Management LLC acquired a new position in RELX PLC, purchasing 5,511 shares valued at approximately $278,000 in the first quarter.
• RELX recently announced a semi-annual dividend of $0.2634 per share, scheduled for payment on September 16th, with an ex-dividend date of August 8th.
• The company's stock has seen a 0.8% increase recently, opening at $46.85, while analysts have varied opinions, with Morgan Stanley maintaining an "overweight" rating and Wall Street Zen downgrading to "hold."

Modern Wealth Management LLC purchased a new stake in Relx Plc (NYSE:RELX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,511 shares of the technology company's stock, valued at approximately $278,000.

A number of other hedge funds also recently made changes to their positions in RELX. Focus Partners Wealth boosted its stake in shares of Relx by 84.9% in the 4th quarter. Focus Partners Wealth now owns 10,235 shares of the technology company's stock valued at $471,000 after purchasing an additional 4,701 shares in the last quarter. Two Sigma Investments LP boosted its position in Relx by 88.9% during the 4th quarter. Two Sigma Investments LP now owns 75,318 shares of the technology company's stock worth $3,421,000 after buying an additional 35,445 shares during the period. Two Sigma Advisers LP boosted its position in Relx by 13.9% during the 4th quarter. Two Sigma Advisers LP now owns 68,463 shares of the technology company's stock worth $3,110,000 after buying an additional 8,363 shares during the period. Vident Advisory LLC boosted its position in Relx by 7.3% during the 4th quarter. Vident Advisory LLC now owns 26,190 shares of the technology company's stock worth $1,190,000 after buying an additional 1,772 shares during the period. Finally, Voloridge Investment Management LLC acquired a new stake in Relx during the 4th quarter worth approximately $1,469,000. 15.02% of the stock is currently owned by institutional investors and hedge funds.

Relx Stock Performance

Relx stock traded down $0.52 during midday trading on Friday, reaching $47.09. The stock had a trading volume of 1,170,348 shares, compared to its average volume of 1,506,443. Relx Plc has a 12 month low of $44.19 and a 12 month high of $56.33. The firm's 50-day moving average price is $49.14 and its 200 day moving average price is $51.05. The firm has a market capitalization of $86.30 billion, a PE ratio of 25.32, a P/E/G ratio of 3.10 and a beta of 0.87. The company has a quick ratio of 0.42, a current ratio of 0.47 and a debt-to-equity ratio of 2.55.

Relx Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, September 16th. Stockholders of record on Friday, August 8th were given a dividend of $0.2634 per share. The ex-dividend date was Friday, August 8th. This represents a dividend yield of 170.0%. Relx's dividend payout ratio is currently 28.49%.

Analyst Upgrades and Downgrades

RELX has been the topic of several recent research reports. Kepler Capital Markets upgraded shares of Relx from a "hold" rating to a "strong-buy" rating in a research report on Thursday. Morgan Stanley restated an "overweight" rating on shares of Relx in a report on Thursday, September 11th. Finally, Wall Street Zen lowered shares of Relx from a "buy" rating to a "hold" rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy".

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.